Cabio Biotech Wuhan Stock Working Capital
| 688089 Stock | 28.83 4.49 18.45% |
Cabio Biotech Wuhan fundamentals help investors to digest information that contributes to Cabio Biotech's financial success or failures. It also enables traders to predict the movement of Cabio Stock. The fundamental analysis module provides a way to measure Cabio Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cabio Biotech stock.
The current year's Net Working Capital is expected to grow to about 779.8 M, whereas Change In Working Capital is projected to grow to (66.4 M). Cabio | Working Capital |
Cabio Biotech Wuhan Company Working Capital Analysis
Cabio Biotech's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Cabio Biotech Working Capital | 596.35 M |
Most of Cabio Biotech's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cabio Biotech Wuhan is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Cabio Net Invested Capital
Net Invested Capital |
|
In accordance with the company's disclosures, Cabio Biotech Wuhan has a Working Capital of 596.35 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The working capital for all China stocks is notably lower than that of the firm.
Cabio Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cabio Biotech's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cabio Biotech could also be used in its relative valuation, which is a method of valuing Cabio Biotech by comparing valuation metrics of similar companies.Cabio Biotech is currently under evaluation in working capital category among its peers.
Cabio Fundamentals
| Return On Equity | 0.0814 | ||||
| Return On Asset | 0.0383 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 4.71 B | ||||
| Shares Outstanding | 168.31 M | ||||
| Shares Owned By Insiders | 50.75 % | ||||
| Shares Owned By Institutions | 4.86 % | ||||
| Price To Book | 3.18 X | ||||
| Price To Sales | 8.74 X | ||||
| Revenue | 443.8 M | ||||
| Gross Profit | 555.03 M | ||||
| EBITDA | 177.62 M | ||||
| Net Income | 91.52 M | ||||
| Total Debt | 11.01 M | ||||
| Book Value Per Share | 9.07 X | ||||
| Cash Flow From Operations | 68.89 M | ||||
| Earnings Per Share | 0.68 X | ||||
| Target Price | 17.0 | ||||
| Beta | 0.6 | ||||
| Market Capitalization | 4.85 B | ||||
| Total Asset | 1.61 B | ||||
| Retained Earnings | 421.34 M | ||||
| Working Capital | 596.35 M | ||||
| Net Asset | 1.61 B | ||||
| Last Dividend Paid | 0.2 |
About Cabio Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cabio Biotech Wuhan's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cabio Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cabio Biotech Wuhan based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Cabio Stock
Cabio Biotech financial ratios help investors to determine whether Cabio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cabio with respect to the benefits of owning Cabio Biotech security.